"Quatrième centre hospitalier en importance au Québec, le CHUS est l’hôpital de proximité des Sherbrookois. Il offre des soins spécialisés et surspécialisés à toute la population de l’Estrie, à toute heure du jour ou de la nuit, tous les jours de l’année."

During the past decade, CHUS-Hopital Fleurimont conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 32 clinical trials were completed, i.e. on average, 168.4% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 8 clinical trials were completed. i.e. 200% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CHUS-Hopital Fleurimont" #1 sponsor was "Radiation Therapy Oncology Group" with 29 trials, followed by "Boehringer Ingelheim" with 10 trials sponsored, "NCIC Clinical Trials Group" with 8 trials sponsored, "Boston Scientific Corporation" with 4 trials sponsored and "European Organisation for Research and Treatment of Cancer - EORTC" with 4 trials sponsored. Other sponsors include 51 different institutions and companies that sponsored additional 42 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CHUS-Hopital Fleurimont" #1 collaborator was "National Cancer Institute (NCI)" with 37 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 8 trials as a collaborator, "NCIC Clinical Trials Group" with 8 trials as a collaborator, "NRG Oncology" with 4 trials as a collaborator and "Cancer and Leukemia Group B" with 3 trials as a collaborator. Other collaborators include 30 different institutions and companies that were collaborators in the rest 32 trials.

According to Clinical.Site data, the most researched conditions in "CHUS-Hopital Fleurimont" are "Prostate Cancer" (11 trials), "Lung Cancer" (8 trials), "Breast Cancer" (7 trials), "Head and Neck Cancer" (7 trials) and "Metastatic Cancer" (5 trials). Many other conditions were trialed in "CHUS-Hopital Fleurimont" in a lesser frequency.

Most popular intervention types in "CHUS-Hopital Fleurimont" are "Drug" (71 trials), "Radiation" (39 trials), "Procedure" (20 trials), "Device" (14 trials) and "Biological" (9 trials). Other intervention types were less common.

The name of intervention was led by "radiation therapy" (33 trials), "Placebo" (15 trials), "conventional surgery" (10 trials), "cisplatin" (8 trials) and "paclitaxel" (8 trials). Other intervention names were less common.

The vast majority of trials in "CHUS-Hopital Fleurimont" are 83 trials for "All" genders, 17 trials for "Female" genders and 11 trials for "Male" genders.

Currently, there are NaN active trials in "CHUS-Hopital Fleurimont". 1 are not yet recruiting, 5 are recruiting, 7 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 86 completed trials in CHUS-Hopital Fleurimont, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in CHUS-Hopital Fleurimont, 8 "Phase 1" clinical trials were conducted, 29 "Phase 2" clinical trials and 51 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 6 trials, and there were also 15 trials that are defined as “Not Applicable".